GSK (NYSE:GSK) Stock Rated “Outperform” in New Coverage at Wolfe Research

Wolfe Research began coverage on shares of GSK (NYSE:GSK) in a research report sent to investors on Friday morning, MarketBeat reports. The firm issued an outperform rating and a $70.00 target price on the pharmaceutical company’s stock.

Several other analysts have also weighed in on GSK. Berenberg Bank set a $60.00 price objective on GSK in a research note on Tuesday, September 15th. Jefferies Financial Group raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 17th. Citigroup assumed coverage on shares of GSK in a report on Friday, July 24th. They issued a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a report on Thursday, July 30th. Finally, Morgan Stanley restated an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, GSK has an average rating of “Hold” and a consensus price target of $55.33.

GSK Trading Down 0.0%

Shares of GSK stock opened at $46.49 on Friday. GSK has a fifty-two week low of $42.85 and a fifty-two week high of $61.69. The stock’s fifty day moving average price is $50.02 and its two-hundred day moving average price is $51.83. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The company has a market cap of $94.05 billion, a PE ratio of 14.54, a P/E/G ratio of 2.09 and a beta of 0.33.

GSK (NYSE:GSK) last issued its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. During the same quarter last year, the company posted $0.47 EPS. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities analysts predict that GSK will post 4.78 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 8th. Stockholders of record on Friday, August 14th were issued a dividend of $0.4515 per share. This represents a $1.81 annualized dividend and a dividend yield of 3.9%. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date was Friday, August 14th. GSK’s dividend payout ratio (DPR) is currently 55.31%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Security National Bank of SO Dak bought a new stake in GSK during the 2nd quarter worth $38,000. Trust Co. of Vermont bought a new position in GSK in the second quarter valued at about $54,000. Philadelphia Investment Partners LLC acquired a new stake in shares of GSK during the second quarter valued at about $70,000. Ancora Advisors LLC acquired a new stake in shares of GSK during the second quarter valued at about $71,000. Finally, Bogart Wealth LLC grew its holdings in shares of GSK by 15.3% during the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after purchasing an additional 200 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “outperform” rating and a $70 price target, implying substantial upside from current levels. Berenberg Bank also reaffirmed its “buy” rating, reinforcing favorable sell-side sentiment.
• Positive Sentiment: GSK plans to invest more than $800 million in a new Upper Merion, Pennsylvania biopharmaceutical facility, which is expected to create approximately 300 jobs. The investment could expand manufacturing and research capacity and strengthen GSK’s U.S. operating footprint. GSK commits $800M to build new Upper Merion facility as pharma investment surges
• Positive Sentiment: AI drug-design company Chai Discovery announced a collaboration with GSK following a successful wet-lab evaluation. The partnership could support faster discovery and development of new medicines, although its financial impact is not yet disclosed. Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation
• Positive Sentiment: GSK is deepening its pipeline through partnerships with Wave Life Sciences on a liver-disease GalNAc-siRNA candidate and AN2 Therapeutics on tuberculosis research, supported by Gates Foundation funding. These deals broaden potential future growth but remain dependent on clinical and regulatory progress. GSK Deepens Its Drug Pipeline Through Two Research Partnerships
• Neutral Sentiment: GSK launched a shingles-awareness campaign with Viola Davis aimed at adults aged 50 and older. The campaign may support vaccine demand and brand awareness, but it is primarily educational and has no quantified near-term revenue impact. Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
• Neutral Sentiment: Investors are looking ahead to GSK’s upcoming quarterly results after the trading window closed. The report remains the next major potential catalyst for valuation and guidance.

About GSK

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.